Patent 9090677 was granted and assigned to Genentech on July, 2015 by the United States Patent and Trademark Office.
The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.